

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

RAFARMA PHARMACEUTICALS INC.

A Wyoming Corporation

12465 South Fort St., Suite 240
Draper UT 84020

307-429-2029

<http://kraspharma.ru/en/>

ilya.spurov@rafarma.group

Quarterly Report
For the Period Ending: 09/30/2021
(the "Reporting Period")

As of 09/30/2021, the number of shares outstanding of our Common Stock was: 87,766,999

As of 12/31/2020, the number of shares outstanding of our Common Stock was: 87,766,999

As of 12/31/2019, the number of shares outstanding of our Common Stock was: 93,166,999

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Rafarma Pharmaceuticals, Inc.
Previously Airprotek International, Inc. 3/2002 – 10/2012
Previously JSN Industries until 03-2002.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g., active, default, inactive):

The Company was organized and incorporated in Nevada in 1982 and continued into the state of Wyoming on October of 2012

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

The Company was acquired by R. & D. BIOCOGENCY LABORATORIES INC. in October of 2020.

The address(es) of the issuer's principal executive office:

Moscow, St. Vorontsovskaya, 20, Russian Federation

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

2) Security Information

Trading symbol:	<u>RAFA</u>
Exact title and class of securities outstanding:	<u>COMMON STOCK</u>
CUSIP:	<u>75062C100</u>
Par or stated value:	<u>.001</u>

Total shares authorized:	<u>300,000,000</u>	as of date: <u>09/30/2021</u>
Total shares outstanding:	<u>87,766,999</u>	as of date: <u>09/30/2021</u>

Number of shares in the Public Float²: 15,405,748 as of date: 09/30/2021
Total number of shareholders of record: 342 as of date: 09/30/2021

All additional class(es) of publicly traded securities (if any):

Trading symbol: N/A
Exact title and class of securities outstanding: Preferred Series "A"
CUSIP: NONE
Par or stated value: .001
Total shares authorized: 30,000,000 as of date: 09/30/2021
Total shares outstanding: 0 as of date: 09/30/2021

Trading symbol: N/A
Exact title and class of securities outstanding: Preferred Series "B"
CUSIP: NONE
Par or stated value: .001
Total shares authorized: 30,000,000 as of date: 09/30/2021
Total shares outstanding: 11,600,000 as of date: 09/30/2021

Transfer Agent

Name: Action Stock Transfer
Phone: 801-274-1088
Email: action@actionstocktransfer.com
Address: 2469 E. Fort Union Blvd., Suite 214
Salt Lake City, UT 84121

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Number of Shares	Opening Balance: Common: <u>83,866,999</u>	*Right-click the rows below and select "Insert" to add rows as needed.
------------------	---	--

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

outstanding as of <u>1/31/2016</u>	Preferred A: <u>30,000,000</u> Preferred B: <u>0</u>								
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g., for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
<u>09/19/2017</u>	<u>New Issue</u>	<u>10,500,000</u>	<u>Preferred Series B</u>	<u>0.001</u>	<u>No</u>	<u>Nickolai Grebenkine</u>	<u>Asset Acquisition</u>	<u>Restricted and non-trading preferred shares</u>	<u>None</u>
<u>9/03/2019</u>	<u>Share Cancellation</u>	<u>30,000,000</u>	<u>Preferred Series A</u>	<u>0.001</u>	<u>No</u>	<u>Cancellation</u>	<u>Cancellation</u>	<u>Cancellation</u>	<u>Cancellation</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>3,000,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Vladimir Dolgolenko</u>	<u>Services Provided as CEO</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>810</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Elizariev Valentin Egorovich</u>	<u>Issuance for cancellation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>231,030</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Marina Gorbacheva</u>	<u>Issuance for cancellation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>2,610</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Posipanova Anna Michaelovna</u>	<u>Issuance for cancellation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>23,850</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Obshchestvo S Ogranichenno y Otvetstvennosti</u>	<u>Issuance for cancellation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/9/2019</u>	<u>New Issue</u>	<u>1,350</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Kazurova Irina Stepanovna</u>	<u>Issuance for cancellation of</u>	<u>Restricted</u>	<u>144</u>

							<u>Preferred Shares</u>		
<u>8/29/2019</u>	<u>New Issue</u>	<u>3,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Reshetov Uriy Vasilevich</u>	<u>Issuance for cancelation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>18,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Bondar Rostislav Vladimirovich</u>	<u>Issuance for cancelation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>1,350</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Smelova Olga Vladimirovna</u>	<u>Issuance for cancelation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>18,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Bondar Vladimir Anatolevich</u>	<u>Issuance for cancelation of Preferred Shares</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>3,000,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>JSC Aetsoft (Nickolai Grebenkine)</u>	<u>Asset Acquisition</u>	<u>Restricted</u>	<u>144</u>
<u>8/29/2019</u>	<u>New Issue</u>	<u>3,000,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Yuriy Martirosyan</u>	<u>Asset Acquisition</u>	<u>Restricted</u>	<u>144</u>
<u>10/6/2020</u>	<u>New Issue</u>	<u>11,600,000</u>	<u>Preferred Series B</u>	<u>0.001</u>	<u>No</u>	<u>R&D Biocogency (Ilya Shpurov)</u>	<u>Asset Transfer</u>	<u>Restricted and non-trading preferred shares</u>	<u>None</u>
<u>10/15/2020</u>	<u>Return to Treasury</u>	<u>5,400,000</u>	<u>Common</u>	<u>.001</u>	<u>Returned</u>	<u>Brindicate Capital LLC (Charles Fleming)</u>	<u>Shares Returned to Treasury</u>	<u>Non Restricted</u>	<u>Returned</u>
<u>12/28/2020</u>	<u>Return to Treasury</u>	<u>11,500,000</u>	<u>Preferred Series B</u>	<u>.001</u>	<u>Returned</u>	<u>Srecko Bojt</u>	<u>Shares Returned to Treasury</u>	<u>Restricted</u>	<u>Returned</u>
Shares Outstanding on <u>09/30/2021</u> :	<u>Ending Balance:</u> Common: <u>87,766,999</u> Preferred A: <u>0</u> Preferred B: <u>11,600,000</u>								

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Ilya Shpurov
Title: Chairman of the Board
Relationship to Issuer: Chairman of the Board

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
D. Statement of income;

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Third Quarter Financial Statements ending 09/30/2021 are incorporated by reference and were posted to OTCIQ on 11/15/2021

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The company was acquired by R&D Biocogency and now owns R&D Biocogency, which includes the following companies: MSCh Slavich LLC, LLC Trading House Slavich, Slavich Noya Technologies LLC.

The company is mainly engaged in the pharmaceutical industry, with several subsidiaries specializing in the production of substances of various products, ultrapure and colloidal chemistry, conducting research in the creation of drugs for cancer, as well as the production and sale of generic drugs.

- B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

Research and development in the field of biocogeneity.

1. LLC MSCH Slavich
<http://msch-slavich.ru/>

2. LLC Trading House Slavich
<http://tdslavich.ru/>

3. Slavich Noya Technologies LLC

Since 1931, the main activity of the enterprise has been the production of products of complex colloidal chemistry, used both in photography and for other purposes of industrial and scientific activities. Our company employs a number of production units, in total about 500 people, who are engaged in:

- Production of ultrapure materials and substances.

We export up to 20 percent of our finished products to more than 60 countries around the world.

C. Describe the issuers' principal products or services, and their markets

1. LLC MSCH Slavich

<http://msch-slavich.ru/>

LLC "MSCh" Slavich "is a multidisciplinary medical organization for 500 medical visits per day. The structure of LLC "MSCh Slavich" includes:

-Polyclinic, where the doctors: therapists, gynecologists, surgeons, neurologists, otorhinolaryngologists, ophthalmologist, psychiatrist, narcologist, cardiologists, allergist-immunologist, endocrinologist, dermatovenerologist, gastroenterologist;

-All types of laboratory tests, functional and ultrasound diagnostics, X-ray examinations and fluorography, endoscopic examinations are carried out.

- Day hospital.

2. LLC Trading House Slavich

<http://tdslavich.ru/>

Slavich is a legendary Russian company with a long history.

LLC "Trading House" Slavich "produces and sells the following types of products:

- cardboard packaging with full-color printing, printing products;
- black and white photographic paper of various types;
- hand antiseptic
- films and photographic films of various types, aerial films;
- photochemicals for processing black and white photographic materials;
- special papers for inkjet printers and plotters, photographic papers for digital photography;
- high-resolution photographic plates, technical, spectrographic and holographic for recording and copying artistic holograms;
- film photosensitive materials for graphic holography, manufacturing of printed circuit boards and prepress printing processes;
- especially pure aluminum and alloys based on it;
- magnetic tapes and tapes for recorders;
- recycles silver-containing waste, including waste photographic plates, waste film, photographic paper waste, waste fixing solutions.

3. Slavich Noya Technologies LLC

Production of ultrapure materials and substances.

Implementation of a project for the construction of a modern plant for the production of domestic substances, both for promotion on the Russian market and for their export.

We export up to 20 percent of our finished products to more than 60 countries around the world.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Properties belonging to the group:

	The address:	Area sq. m.
1	Pereslavl-Zalessky, pl. Mendeleev house 2, building number 73	2 167,80
2	Pereslavl-Zalessky, pl. Mendeleev house 2, building number 45a	36 847,30
3	Pereslavl-Zalessky, pl. Mendeleev house 2, building number 105	2 528,90
4	Pereslavl-Zalessky, pl. Mendeleev house 2, building number 73i	293,40
5	Pereslavl-Zalessky, pl. Mendeleev house 2, building 73 g	461,70
6	Pereslavl-Zalessky, pl. Mendeleev house 2, building number 130	7 430,30
7	Pereslavl-Zalessky, pl. Mendeleev house 2, building number 139	503,30
8	Pereslavl-Zalessky, pl. Mendeleev house 2, Warehouse-anagar No. 1	1 004,10

9	Pereslavl-Zalessky, pl. Mendeleev building 2, building No. 139. Warehouse- hangar No. 2	903,00
10	Pereslavl-Zalessky, pl. Mendeleev house 2, bldg. 13	3 570,20
11	Pereslavl-Zalessky, pl. Mendeleev house 2, bldg. 45	9 236,20
12	TOTAL	64 946,20

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
R. & D. BIOCOGENCY LABORATORIES INC. LTD (Ilya Shpurov)	Chairman of the Board	Cyprus	11600000	Preferred B	100%	
MICHAEL KOROVKIN	President	Bomarzo (VT), Italia	0	n/a	n/a	
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____

_____	_____	_____	_____	_____	_____	_____
-------	-------	-------	-------	-------	-------	-------

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Amber Barger
Firm: LAW OFFICES OF M. AMBER BARGER, PLLC
Address 1: 3901 Arlington Highlands Blvd., Suite 200
Address 2: Arlington, TX 76018
Phone: (682) 888-1748
Email: abarger@mablawoffice.com

Accountant or Auditor

Name: _____

Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Ilya Shpurov certify that:

1. I have reviewed this Third Quarter Disclosure Statement of RAFARMA PHARMACEUTICALS INC;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/15/2021

/s/ Ilya Shpurov

Principal Financial Officer:

I, Ilya Shpurov certify that:

1. I have reviewed this Second Quarter Disclosure Statement of RAFARMA PHARMACEUTICALS INC;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/15//2021

/s/ Ilya Shpurov